PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report - Top-Institutions - MDSpire

PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report

  • By

  • Zixin Li

  • Xuezhou Pang

  • Zhongyao Wang

  • Jing Wen

  • Yanli Zhao

  • Daiyuan Ma

  • Jianquan Yang

  • May 8, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Gynecologic Oncology

  • #2

    Institut Gustave Roussy
    Institut Gustave Roussy

    Villejuif, France

    Key Differentiators

    • Oncology

  • #3

    The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai
    The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai

    New York, New York

    Key Differentiators

    • Oncology

  • #4

    Cancer Hospital, Chinese Academy of Medical Sciences
    Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China

    Key Differentiators

    • Oncology

  • #5

    Zhongnan Hospital of Wuhan University
    Zhongnan Hospital of Wuhan University

    Wuhan, China

    Key Differentiators

    • Oncology

Original Source(s)

PRaG5.0 combined with chemotherapy and sequential chemoimmunotherapy for massive SMARCA4-deficient undifferentiated tumor of the cervix: case report

  • by Zixin Li, Xuezhou Pang, Zhongyao Wang, Jing Wen, Yanli Zhao, Daiyuan Ma, Jianquan Yang

  • May 8, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer

At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, presented positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.

  • by

  • June 1, 2026

  • 5 min
Complete radiographic response to immunotherapy in a patient with metastatic anaplastic thyroid cancer – a case report and review of the literature